| 思拓凡(Cytiva) | Pall生命科学业务 | 未披 | 强化生物工艺和医疗 | | --- | --- | --- | --- | | | | 露 | 产品组合 | | 伟励拓(Veralto) | 未披露具体收购 | 未披 | 深入诊断终端市场 | | | | 露 | | | 伟励拓(Veralto) | Axine Water | 未披 | 拓展废水处理技术 | | | Technologies少数股权 | 露 | | | 沃特世(Waters) | BD生物科学业务 | 175 | 扩大生命科学与诊断 | | | | 亿美 | 领域 | | | | 元 | | | 西门子(SIMIENS) | Dotmatics | 51亿 | 强化AI驱动产品生命 | | | | 美元 | 周期管理 | | 因美纳(Illumina) | SomaLogic及其他指定资 | 3.5亿 | 推进蛋白质组学检测 | | | 产 | 美元 | | | 因美纳(Illumina) | Fluent BioSciences | 未披 | 拓展单细胞技术领域 | | | | 露 | | 特别提示 微信公众号机制调整， ...

Thermo Fisher Scientific (NYSE:TMO) shares are trading higher on Wednesday after the company inked a deal to acquire Clario Holdings for $8.875 billion in cash, plus potential future earnout and other performance-based payments. • TMO stock is moving in positive territory. Track the latest developments here.The DetailsNotably, Clario centralizes clinical trial endpoint data from devices, sites and patients, allowing pharma and biotech companies to digitally collect, manage, and analyze evidence across all p ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Thermo Fisher Scientific has reached a definitive agreement to acquire clinical trial endpoint data solutions provider Clario Holdings for $8.875bn in cash upon completion of the deal. Clario will be acquired from a shareholder group spearheaded by Astorg and Nordic Capital, along with Cinven and Novo Holding. Clario is known for integrating endpoint data of the trial from various sources, including clinical sites, subjects, and devices. This integration facilitates biotech and pharmaceutical companies ...

格隆汇10月29日｜赛默飞世尔宣布，将以高达94亿美元的价格收购私营数据管理公司Clario，在美国需 求强劲反弹的背景下加强其临床试验研究业务。这是赛默飞世尔今年的第三次重大收购。这笔交易预计 将于2026年初完成，交易完成后第一年的调整后每股收益将增加45美分。 ...

Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, strengthening its clinical trial research business amid a strong rebound in demand in... ...

来源：视频滚动新闻 美股周三盘前，赛默飞世尔Thermo Fisher (TMO)股价小幅上扬。据报道，正接近以100亿美元收购临床 试验软件公司Clario。此举符合赛默飞世尔扩大其在临床试验数据管理领域能力的战略。上述收购交易 可能很快宣布，但条款可能会有变动。 ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Thermo Fisher Scientific will acquire clinical trial data firm Clario Holdings for $8.9 billion in cash, the companies announced Wednesday. Clario is currently held by a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven. In addition, Thermo has agreed to pay $125 million in January 2027, and up to $400 million in payments base ...

智通财经APP获悉，美国生命科学工具与体外诊断领军者赛默飞世尔(TMO.US)已确认达成收购协议， 将以在交割时支付的88.75亿美元现金，从由Astorg和Nordic Capital、Novo Holding以及Cinven领导的股 东集团手中实现收购临床试验数据管理公司Clario Holdings。对于赛默飞世尔而言，吞下Clario，将进一 步强化"数字化临床证据"业务能力，该项交易具备即刻增厚利润率与调整后EPS的财务层面吸引力，并 押注FDA引导的DHT/DCT(数字健康技术/去中心化试验)长期趋势。 此次收购将在交割后的第一年即对赛默飞世尔的调整后营业利润率产生积极的增厚效应，并在交割后第 一年为调整后的每股收益增加0.45美元。该公司预计在完成交割之后第5年实现大约1.75亿美元的协同后 的调整营业利润。 有分析师表示，赛默飞世尔收购Clario，是在旗下的PPD(CRO)之后进一步强化"数字化临床证据"能力： 把 eCOA、医学影像、心电/呼吸、安全性监测、可穿戴与站点数据等"终点数据平台"纳入自家体系，把 药物从研发—临床—注册—商业化的证据链条打通并数据化，从而获得更高客户黏性、交叉销 ...

Let's bring in Sarra Seth, managing partner and portfolio manager at Douglas C. Lane and Associates. He's also a CNBC contributor.Satra, good morning. Good to see you. >> Good morning, Frank.>> All right, we got to start with Nvidia. Uh, looking like it could open above $5 trillion for a market cap when at the opening bell. What does that say to you about the AI trade in this stock in particular.>> Look, I think the AI trade is going very strong. Nvidia's announced quite a few agreements. You you've seen it ...